<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202068</url>
  </required_header>
  <id_info>
    <org_study_id>GC0048-015</org_study_id>
    <nct_id>NCT04202068</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Efficacy and Safety of CRO-SBT in the Treatment of Gonorrhea</brief_title>
  <acronym>CRO-SBT</acronym>
  <official_title>A Study Evaluating Efficacy and Safety of Ceftriaxone Sodium and Sulbactam Sodium for Injection in the Treatment of Uncomplicated Urogenital Gonorrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangbei Welman Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangbei Welman Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phaseIV, multicenter, open-label，single arm study which will be performed to
      evaluate efficacy and safety of Ceftriaxone sodium and Sulbactam Sodium for injection for the
      treatment of uncomplicated urogenital infection caused by Neisseria gonorrhoeae in adolescent
      and adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, adults will be administered as one 3g IV dose at the study site,Children under
      12 will be administered as one 75mg/kg IV dose . Approximately 100 subjects will be recruited
      to receive study treatment. The duration of the study will be approximately 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 3, 2015</start_date>
  <completion_date type="Actual">May 30, 2016</completion_date>
  <primary_completion_date type="Actual">May 3, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Ceftriaxone sodium and Sulbactam Sodium for injection</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bacterial eradicatio</measure>
    <time_frame>Up to Day 8</time_frame>
    <description>Number of subjects with culture-confirmed bacterial eradication of Neisseria gonorrhoeae from the urogenital site at the Test-of-Cure (TOC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical cure</measure>
    <time_frame>Up to Day 8</time_frame>
    <description>Number of subjects with disappearance of clinical symptoms and signs at the Test-of-Cure (TOC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comprehensive curative effect</measure>
    <time_frame>Up to Day 8</time_frame>
    <description>Number of subjects with culture-confirmed bacterial eradication of Neisseria gonorrhoeae from the urogenital site and disappearance of clinical symptoms and signs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Gonorrhea</condition>
  <arm_group>
    <arm_group_label>Ceftriaxone sodium and Sulbactam Sodium for injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combinations of β-Lactamase inhibitors</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone sodium and Sulbactam Sodium for injection</intervention_name>
    <description>Ceftriaxone sodium and Sulbactam Sodium for injection is available as sterile powder for reconstitution.It will be administered as one 3g IV dose for adult or one 75mg/kg IV dose for children under 12.</description>
    <arm_group_label>Ceftriaxone sodium and Sulbactam Sodium for injection</arm_group_label>
    <other_name>CRO-SBT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be &gt;=6 or ≦80 years of age at the time of signing the informed
             consent,both gender

          -  Subjects having clinical suspicion of a urogenital gonococcal infection with or
             without gonococcal infection according to the laboratory test results of symptoms,
             physical symptoms, gonococcus smear, culture, etc.

          -  Subjects having clinical suspicion of a gonococcal infection must have both of the
             following risk factors:once used three generations of cephalosporin invalid, and
             sensitive to this product (including gonorrhea urethritis, cervicitis, proctitis,
             pharyngitis).

          -  Male and female subject must agree to use contraception (male condoms) during
             intercourse from the Baseline Visit through completion of the TOC Visit.

        Exclusion Criteria:

          -  Subject has a history of sensitivity to the study treatments, or components thereof,
             or a history of a drug (including erythromycin and any macrolide or ketolide drug) or
             other allergy that, in the opinion of the investigator or medical monitor,
             contraindicates his or her participation

          -  Subject has received any cephalosporinl therapy for the treatment of a gonococcal
             infection

          -  Pregnant or lactating women, or women Subject of childbearing age who were unwilling
             or unable to use acceptable methods of contraception throughout the study period.

          -  Famale subject who were positive for pregnancy tests at the time of inclusion or
             before the start of study drug use.

          -  Subject has risk of potentially serious drug interactions

          -  Subject has major diseases such as cardiovascular disease, hepatorenal disease and
             mental disease, or other factors, the researcher should not participate in the study
             according to comprehensive judgment

          -  Subject has a known history of alcohol or drug abuse

          -  Subject has a known any complicated or systemic gonorrhea infection, such as pelvic
             inflammatory disease, arthritis, endocarditis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>pingyu P Zhou, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Dermatology Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>shunming S Xu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>People's Hospital of Shanghai Pudong New Area</affiliation>
  </overall_official>
  <overall_official>
    <last_name>yanyue Tong, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>People's Hospital of Quzhou</affiliation>
  </overall_official>
  <overall_official>
    <last_name>zhehu Jin, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Hospital of Yanbian University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>bo Cheng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Fujian Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>wuqing W Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Central Hospital of Shanghai Minhang District</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ping Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The third people's hospital of Hangzhou</affiliation>
  </overall_official>
  <link>
    <url>http://mall.cnki.net/magazine/Article/YWLX201406022.htm</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>December 15, 2019</last_update_submitted>
  <last_update_submitted_qc>December 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gonorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Sulbactam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

